Voya Investment Management LLC lifted its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 2,786.1% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 568,525 shares of the biotechnology company’s stock after purchasing an additional 548,826 shares during the quarter. Voya Investment Management LLC owned 0.88% of Sarepta Therapeutics worth $19,165,000 as of its most recent filing with the SEC.

Other large investors have also added to or reduced their stakes in the company. Prentiss Smith & Co. Inc. increased its holdings in shares of Sarepta Therapeutics by 772.2% during the second quarter. Prentiss Smith & Co. Inc. now owns 3,576 shares of the biotechnology company’s stock valued at $121,000 after purchasing an additional 3,166 shares during the period. Ameritas Investment Partners Inc. bought a new stake in shares of Sarepta Therapeutics during the first quarter valued at about $127,000. PNC Financial Services Group Inc. raised its stake in shares of Sarepta Therapeutics by 150.1% during the first quarter. PNC Financial Services Group Inc. now owns 4,666 shares of the biotechnology company’s stock valued at $138,000 after purchasing an additional 2,800 shares in the last quarter. Edge Wealth Management LLC bought a new stake in shares of Sarepta Therapeutics during the second quarter valued at about $175,000. Finally, BNP Paribas Arbitrage SA raised its stake in shares of Sarepta Therapeutics by 448.5% during the second quarter. BNP Paribas Arbitrage SA now owns 6,489 shares of the biotechnology company’s stock valued at $219,000 after purchasing an additional 5,306 shares in the last quarter. 65.41% of the stock is owned by institutional investors.

Sarepta Therapeutics, Inc. (NASDAQ SRPT) opened at 49.55 on Tuesday. The firm’s 50-day moving average is $42.14 and its 200 day moving average is $35.85. Sarepta Therapeutics, Inc. has a 52-week low of $26.26 and a 52-week high of $63.03. The stock’s market capitalization is $3.19 billion.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Wednesday, July 19th. The biotechnology company reported ($0.46) EPS for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.46. The company had revenue of $35.01 million during the quarter, compared to the consensus estimate of $22.52 million. The business’s revenue was up 350000.0% compared to the same quarter last year. During the same period last year, the company earned ($1.19) earnings per share. On average, equities analysts forecast that Sarepta Therapeutics, Inc. will post ($1.22) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Sarepta Therapeutics, Inc. (SRPT) Stake Lifted by Voya Investment Management LLC” was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another publication, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be viewed at https://www.watchlistnews.com/sarepta-therapeutics-inc-srpt-stake-lifted-by-voya-investment-management-llc/1605301.html.

SRPT has been the subject of a number of recent analyst reports. Janney Montgomery Scott increased their target price on shares of Sarepta Therapeutics from $65.00 to $73.00 and gave the company a “fair value” rating in a research report on Monday, July 24th. Credit Suisse Group raised their target price on shares of Sarepta Therapeutics from $5.65 to $81.00 and gave the company an “outperform” rating in a research note on Thursday, September 7th. Nomura restated a “buy” rating and set a $84.00 price target on shares of Sarepta Therapeutics in a research report on Tuesday, September 5th. Needham & Company LLC restated a “buy” rating and set a $75.00 price target on shares of Sarepta Therapeutics in a research report on Wednesday, September 6th. Finally, Zacks Investment Research lowered shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, July 17th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and fifteen have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $62.79.

In related news, CFO Sandesh Mahatme sold 50,000 shares of the business’s stock in a transaction that occurred on Thursday, July 20th. The shares were sold at an average price of $41.00, for a total transaction of $2,050,000.00. Following the completion of the transaction, the chief financial officer now owns 41,736 shares in the company, valued at $1,711,176. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Alexander Cumbo sold 5,918 shares of the business’s stock in a transaction that occurred on Thursday, July 20th. The shares were sold at an average price of $41.00, for a total transaction of $242,638.00. Following the transaction, the senior vice president now owns 22,793 shares of the company’s stock, valued at approximately $934,513. The disclosure for this sale can be found here. Insiders sold a total of 78,056 shares of company stock worth $3,224,208 over the last quarter. 9.60% of the stock is currently owned by corporate insiders.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Institutional Ownership by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.